Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

Discerning the genetics and epigenetics of chronic rhinosinusitis (CRS) may optimize
outcomes through early diagnostics, personalized and novel therapeutics, and early …

A cystic fibrosis (CF) transmembrane conductor regulator (CFTR) gene modulating triple
therapy combining elexacaftor-tezacaftor-ivacaftor (Trikafta) has been recently discovered …

Cystic Fibrosis (CF) is a genetic disease caused by mutations in CFTR gene expressing the
anion selective channel CFTR located at the plasma membrane of different epithelial cells …

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation,
respiratory symptoms, inflammation of the airways, and systemic manifestations of the …

This short report documented cystic fibrosis transmembrane conductance regulator (CFTR)
variants in 37 patients with cystic fibrosis (CF) in the Rio Grande do Norte region of …

In an era of unparalleled technical advancement, the pharmaceutical industry is struggling to
transform data into increased research and development efficiency, and, as a corollary, new …

Recent studies have shown that therapy with Cystic fibrosis transmembrane conductance
regulator (CFTR) modulators in Cystic Fibrosis (CF) patients with Elexacaftor-Tezacaftor …

Cystic fibrosis is the most common lethal genetic disease in the white population, affecting
approximately 80 000 people worldwide. It is an autosomal recessive, monogenic, and …

The TMEM16A chloride channel is proposed as a therapeutic target in cystic fibrosis, where
activation of this ion channel might restore airway surface hydration and mitigate respiratory …